School of Medicine


Showing 11-20 of 38 Results

  • Alireza Ghiam, MD, MS

    Alireza Ghiam, MD, MS

    Clinical Associate Professor, Radiation Oncology - Radiation Therapy

    BioDr. Ghiam is an American and Canadian Board-Certified Radiation Oncologist with the Stanford Medicine Cancer Center and a Clinical Associate Professor in the Department of Radiation Oncology at Stanford University School of Medicine. After completing an MSc in Molecular Biology & Genetics at the University of Montreal, he completed a residency in Radiation Oncology and fellowship in Head & Neck and GU radiation oncology at the University of Toronto.

    He diagnoses and treats various conditions specializing in head & neck cancer, genitourinary malignancies, and metastatic disease. His treatment expertise includes oligometastatic disease, palliative radiation therapy, stereotactic ablative radiotherapy, and proton therapy.

    Dr. Ghiam has contributed to the field through his authorship of technology- and biology-based publications and collaboration in clinical trials. He has been recognized by awards from the American Society for Radiation Oncology (ASTRO), the Canadian Association of Radiation Oncology (CARO), and the Universities of Toronto and Pennsylvania. In recognition of his educational work, he received two prestigious teaching awards for teaching residents and medical students. He has presented his research work nationally and internationally and authored and co-authored several papers.

    Dr. Ghiam's interest lies in exploring novel AI-powered technologies that can enhance patient outcomes, and bridge health equity gaps in radiation oncology. He is also interested in clinical trials of innovative radiation therapy techniques with a focus on leveraging technology and biology to reduce toxicity and increase precision.

    Dr. Ghiam has now joined the prestigious Radiation Oncology Department of Stanford University, where he is dedicated to academia, education, and diversity. He is committed to improving patient outcomes and changing the role of supportive care in radiation oncology by promoting quality standards and utilizing palliative radiotherapy to enhance the quality of life for his patients.

    Dr. Ghiam practices evidence-based care with compassion and treats his patients as he would his own family.

  • Iris C. Gibbs, MD, FACR, FASTRO

    Iris C. Gibbs, MD, FACR, FASTRO

    Professor of Radiation Oncology (Radiation Therapy) and, by courtesy, of Neurosurgery
    On Partial Leave from 07/05/2023 To 09/29/2023

    Current Research and Scholarly InterestsDr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.

  • Steven Hancock, MD

    Steven Hancock, MD

    Professor of Radiation Oncology (Radiation Therapy), Emeritus

    Current Research and Scholarly InterestsOutcomes of radiation treatment for prostate cancer. Clinical research interests in the late effects of radiation on normal tissues and chemical modification of radiation injury. Hodgkins's disease and late effects of radiation and combined modality therapy. Radiation sensitizers. Hypoxic cell cytotoxins. Esophageal cancers.
    General adult and pediatric radiation therapy.

  • Richard Hoppe

    Richard Hoppe

    Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology

    Current Research and Scholarly InterestsIrradiation immunosuppression; total body irradiation;, psychosocial effects of cancer treatment; treatment of lymphoma;, mycosis fungoides.

  • Anusha Kalbasi, M.D.

    Anusha Kalbasi, M.D.

    Associate Professor of Radiation Oncology (Radiation Therapy)

    BioDr. Kalbasi is a board-certified radiation oncologist and physician-scientist at the Stanford Cancer Institute. He is also an associate professor of radiation oncology at Stanford Medicine and a project member of the Parker Institute for Cancer Immunotherapy.

    Dr. Kalbasi specializes in the diagnosis and treatment of solid tumors, especially sarcoma and melanoma, with a focus on bringing new treatments to patients. This focus includes using advanced techniques in cancer immunotherapy, including CAR T-cell therapy and innate immune agonists.

    Dr. Kalbasi's NIH-funded laboratory is actively engaged in translational research with a special focus on developing new immunotherapy treatments for patients with solid tumors, especially sarcoma. A primary focus of his ongoing research involves identifying why some patients do not benefit from treatments like immunotherapy or radiation, then designing and testing strategies to overcome treatment resistance. Dr. Kalbasi is also an experienced leader of clinical trials related to immunotherapy, T cell therapy and radiation therapy, and is a recipient of the Damon Runyon Clinical Investigator Award.

    Prior to his arrival at Stanford Health Care, Dr. Kalbasi was assistant professor of radiation oncology in the David Geffen School of Medicine at UCLA and chief of sarcoma radiotherapy at the UCLA Jonsson Comprehensive Cancer Center. During his tenure, he was named a NextGen Star by the American Association of Cancer Research in recognition for excellence in cancer research.

    Dr. Kalbasi’s work has been published in leading journals including Nature, Science Translational Medicine, JAMA Oncology, Lancet Oncology, Nature Cancer and Cancer Discovery. He has served as a peer reviewer for multiple prestigious journals, including the Proceedings of the National Academy of Sciences, Cell and the Journal of Clinical Investigation. He has also presented research to his peers at the American Association for Cancer Research and the American Institute of Chemical Engineers.

  • Daniel Kapp

    Daniel Kapp

    Professor of Radiation Oncology, Emeritus

    Current Research and Scholarly InterestsGynecologic malignancies; Rectal/and cancer; Breast Cancer; Hodgkin's disease; Hyperthermia; intraoperative radiation therapy; High dose rate radiation therapy; Predictive assays; Patterns of tumor spread; Health care finance.